Identification of the human cytochrome P450s responsible for the in vitro metabolism of a leukotriene B4 receptor antagonist, CP-195,543

Xenobiotica

Volumn 33, Issue 12, 2003, Pages 1201-1210

  Khojasteh Bakht, S C ^a,b   Rossulek, M I ^a   Fouda, H G ^a   Prakash, C ^a  

^a PFIZER INC   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CP 195 543; CYTOCHROME P450; CYTOCHROME P450 3A; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTEREOISOMER; DRUG METABOLISM; DRUG OXIDATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LIVER CLEARANCE; LIVER MICROSOME; LIVER MICROSOME METABOLISM; PROTEIN ANALYSIS; PROTEIN FUNCTION;

ADOLESCENT; ADULT; AGED; CHROMANS; COUMARINS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; HUMANS; KETOCONAZOLE; KINETICS; MALE; MEPHENYTOIN; MICROSOMES, LIVER; MIDDLE AGED; NADP; OXIDATION-REDUCTION; QUINIDINE; RECEPTORS, LEUKOTRIENE B4; RECOMBINANT PROTEINS; SULFAPHENAZOLE; THEOPHYLLINE;

STAPHYLOCOCCUS PHAGE 3A;

EID: 1642539179     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250310001646362     Document Type: Article

References (22)

1. BUTLER, M. A., GUENGERICH, F. P. and KADLUBAR, F. F., 1989, Metabolic oxidation of the carcinogens 4-aminobiphenyl and 4,4′-methylenebis(2- chloroaniline) by human hepatic microsomes and by purified rat hepatic cytochrome P-450 monooxygenases. Cancer Research, 49, 25-31.
2. CARLOS, T. M. and HARLAN, J. M., 1994, Leukocyte-endothelial adhesion molecules. Blood, 84, 2068-2101.
3. CROOKS, S. W. and STOCKLEY, R. A., 1998, Leukotriene B4. International Journal of Biochemistry and Cell Biology, 30, 173-178.
4. DALVIE, D. K. and O'DONNELL, J. P., 1999, Metabolism of CP-195,543, a leukotriene B4 receptor antagonist, in the Long-Evans rat and cynomolgus monkey. Xenobiotica, 29, 1123-1140.
5. DOMANSKI, D. L., FINTA, C., HALPERT, J. R. and ZAPHIROPOULOS, P. G., 2001, cDNA cloning and initial characterization of cYP3A43, a novel human cytochrome P450. Molecular Pharmacology, 59, 386-392.
6. FORD-HUTCHINSON, A. W., BRAY, M. A., DOIG, M. V., SHIPLEY, M. E. and SMITH, M. J. H., 1980, Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature (London), 286, 264-265.
7. GELLNER, K., EISELT, R., HUSTERT, E., ARNOLD, H. KOCH, I., HABERL, M., DEGLMANN, C. J., BURK, O., BUNTEFUSS, D. and ESCHER S., 2001, Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics, 11, 111-121.
8. GUENGERICH, F. P., 2000, Pharmacogenomics of cytochrome P450 and other enzymes involved in biotransformation of xenobiotics. Drug Development Research, 49, 4-16.
9. KRONBACH, T., MATHYS, D., GUT, J., CATIN, T. and MEYER, U. A., 1987, High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Annals of Biochemistry, 162, 24-32.
10. LI, A. P., KAMINSKY, D. L. and RASMUSSEN, A., 1995, Substrate of human hepatic cytochrome P450 3A4. Toxicology, 104, 1-8.
11. LIN, J. H., CHIBA, M. and BAILLIE, T. A., 1999, Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacology Reviews, 51, 135-158.
12. LIN, J. H. and LU, A. Y., 1998, Inhibition and induction of cytochrome P450 and the clinical implication. Clinical Pharmacokinetics, 35, 361-390.
13. MEIER, U. T., KRONBACH, T. and MEYER, U. A., 1985, Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Annals of Biochemistry, 151, 286-291.
14. MINERS, J. O., SMITH, K. J., ROBSON, R. A., MCMANUS, M. E., VERONESE, M. E. and BIRKETT, D. J., 1988, Tolbutamide hydroxylation by human liver microsomes. Kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochemical Pharmacology, 37, 1137-1144.
15. OMURA, T. and SATO, R., 1964, The carbon monoxide binding pigment of liver microsmes. Journal of Biological Chemistry, 239, 3137-3142.
16. ORTIZ DE MONTELLANO, P., MICO, B. A., MATHEWS, J. M., KUNZE, K. L., MIWA, G. T. and LU, A. Y. H., 1981, Selective inactivation of cytochrome P-450 isozymes by suicide substrates. Archives of Biochemistry and Biophysics, 210, 717-728.
17. PRAKASH, C., KAMEL, A., CUI, D., WHALEN, R. D., MICELI, J. and TWEEDIE, D., 2000, Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. British Journal of Clinical Pharmacology, 49(suppl.), 35S-42S.
18. SHOWELL, H. J., CONKLYN, M. J., ALPERT, R., HINGORANI, G. P., WRIGHT, K. F., SMITH, M. A., STAM, E., SALTER, E. D., SCAMPOLI, D. N., MELTZER, S., REITER, L. A., KOCH, K., PISCOPIO, A. D., CORTINA, S. R., LOPEZ-ANAYA, A., PETTIPHER, E. R., MILICI, A. J. and GRIFFITHS, R. J., 1998, The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195,543. Journal of Pharmacology and Experimental Therapeutics, 285, 946-954.
19. SONDERFAN, A. J., ARLOTTO, M. P., DUTTON, D. R., MCMILLEN, S. K. and PARKINSON, A., 1987, Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Archives of Biochemistry and Biophysics, 255, 27-41.
20. THUMMEL, K. E. and WILKINSON, G., 1998, In vitro and in vivo drug interactions involving human CYP3A. Annual Reviews in Pharmacology and Toxicology, 38, 389-430.
21. WILLIAMS, J. A., RING, B. J., CANTRELL, V. E., JONES, D. R., ECKSTEIN, J., RUTERBORIES, K, HAMMAN, M. A., HALL, S. D. and WRIGHTON, S. A., 2002, Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metabolism and Disposition, 30, 883-891.
22. WRIGHTON, S. A., VANDENBRANDEN, M. and RING, B. J., 1996, The human drug metabolizing cytochrome P450. Journal of Pharmacokinetics and Biopharmacology, 24, 461-473.